Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation-Reference-Cited by-同舟云学术

Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation

Author:

Yabe Daisuke¹^ORCID,Hamamoto Yoshiyuki¹²³,Seino Yusuke⁴,Kuwata Hitoshi¹²,Kurose Takeshi¹²,Seino Yutaka¹²

Affiliation:

1. Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan

2. Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan

3. Center for Metabolism and Clinical Nutrition, Kansai Electric Power Hospital, Osaka, Japan

4. Departments of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan

Funder

Japan Science and Technology Agency

Japan Vascular Disease Research Foundation

Japan Association for Diabetes Education and Care

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

Reference43 articles.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献